![](https://webarchive.library.unt.edu/eot2008/20090511130740im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090511130740im_/http://www.cancer.gov/images/spacer.gif)
anti-PD-1 human monoclonal antibody MDX-1106 A fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity. Anti-PD-1 human monoclonal antibody MDX-1106 binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens.
Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090511130740im_/http://www.cancer.gov/images/spacer.gif)
Code names: | ![](https://webarchive.library.unt.edu/eot2008/20090511130740im_/http://www.cancer.gov/images/spacer.gif) | MDX-1106 ONO-4538 | | ![](https://webarchive.library.unt.edu/eot2008/20090511130740im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090511130740im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090511130740im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090511130740im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090511130740im_/http://www.cancer.gov/images/spacer.gif) |